From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence
Abstract
Background
Chronic orofacial pain (OFP) comprises musculoskeletal, neuropathic and nociplastic disorders, yet first-line drug selection remains largely empirical and is frequently extrapolated from spinal and peripheral neuropathic pain.
Objective
To quantify the evidence underpinning pharmacotherapy of the four principal ICOP-2020 disorders and to appraise psychophysical, neurophysiological and dental markers as candidate predictors of treatment response.
Methods
Structured review of PubMed/MEDLINE and Cochrane sources to October 2026 (meta-analyses, randomised controlled trials [RCTs] and large observational cohorts). Estimates were extracted as reported; where only counts or confidence intervals were available, odds/risk ratios with 95% CI and exact two-sided p values were computed (Fisher’s exact test; Altman–Bland method).
Results
Prevalence spanned three orders of magnitude, from 31.1% for temporomandibular joint disorders to 0.03% for persistent idiopathic facial pain. OFP-specific randomised evidence was small (burning mouth syndrome: 23 RCTs, 1,121 participants), whereas neuropathic-pain recommendations rest on 313 trials (48,789 participants) that excluded idiopathic OFP; first-line numbers needed to treat increased between 2015 and 2025 (tricyclics 3.6→4.6; SNRIs 6.4→7.4). Patients with TMD had lower remote pressure pain thresholds (SMD −1.92; p<0.01), and non-paroxysmal OFP showed enhanced temporal summation (SMD 0.30; p=0.002), whereas impaired conditioned pain modulation (CPM) did not reach significance (p=0.066; I²=98%). Mechanism-stratified studies outside the face showed phenotype-dependent efficacy (CPM–duloxetine r=0.628, p<0.001; oxcarbazepine phenotype interaction p=0.047). Bruxism was associated with TMD (OR 2.25; p<0.001), but self-reported sleep bruxism discriminated cases from controls (OR 6.89; p<0.001) whereas polysomnography did not (OR 0.88; p=0.78).
Conclusions
Current evidence supports, but has not yet tested, phenotype-guided first-line drug selection in chronic OFP. Prospective trials combining standardised psychophysics, trigeminal neurophysiology and instrumentally verified dental factors are required; a testable phenotype-to-drug framework is proposed.
Keywords
orofacial pain; temporomandibular disorders; burning mouth syndrome; trigeminal neuralgia; quantitative sensory testing; conditioned pain modulation; bruxism; personalised pharmacotherapy
Full article
How to cite
Giyazova M. M., Olimov S. Sh. (2026). From empirical to phenotype-guided pharmacotherapy of chronic orofacial pain: a structured review and quantitative synthesis of epidemiological, pharmacological, psychophysical and dental evidence. Journal of Taibah University Medical Sciences, 21(5), 1199–1207. DOI: 10.14419/j.jtumed.2026.10.12.
Recommended articles
Clinical and Functional Phenotypes of Hypertension and Early Cardiovascular Remodeling in Young Men Serving in the Security and Defense Agencies of the Republic of Uzbekistan
Journal of Taibah University Medical Sciences · 05-09-2026
Systemic and local immune responses in children with apical periodontitis and their modification by adjunctive immunotropic treatment
Journal of Taibah University Medical Sciences · 14-09-2026
Cardiovascular Disease in the Structure of Unfitness for Military Service: A Clinical-Epidemiological Analysis of Expert Decisions and a Prognostic Model of an Unfavorable Expert Outcome
Journal of Taibah University Medical Sciences · 06-09-2026
Exposure of unmonitored workers to ionizing radiation due to portable X-ray machine use and area dose mapping in an emergency department
Journal of Taibah University Medical Sciences · October 2026